MiNK Therapeutics Files 8-K with Material Agreement
Ticker: INKT · Form: 8-K · Filed: Jul 15, 2025 · CIK: 1840229
Sentiment: neutral
Topics: material-agreement, financial-statements, corporate-update
TL;DR
MiNK Therapeutics filed an 8-K on 7/15/25, reporting a material definitive agreement and financial statements.
AI Summary
On July 15, 2025, MiNK Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also includes financial statements and exhibits. MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc., with a name change occurring on January 12, 2021.
Why It Matters
This filing signals a significant development for MiNK Therapeutics, potentially involving a new partnership, acquisition, or financing, which could impact its stock price and future operations.
Risk Assessment
Risk Level: medium — An 8-K filing indicates significant corporate events, which can introduce volatility and uncertainty for investors.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former Company Name
- July 15, 2025 (date) — Date of Report
- January 12, 2021 (date) — Date of Name Change
FAQ
What is the nature of the material definitive agreement entered into by MiNK Therapeutics, Inc. on or before July 15, 2025?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What financial statements and exhibits are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
When did MiNK Therapeutics, Inc. change its name from AgenTus Therapeutics, Inc.?
The company changed its name from AgenTus Therapeutics, Inc. on January 12, 2021.
What is the principal executive office address for MiNK Therapeutics, Inc.?
The principal executive offices are located at 149 Fifth Avenue, Suite 500, New York, New York 10010.
What is the SIC code for MiNK Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for MiNK Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 15, 2025 regarding MiNK Therapeutics, Inc. (INKT).